Vertex Pharmaceuticals: Valuation Gets Steep Despite CF Dominance
With a $40 billion valuation, expectations have risen quite a bit to the extent that investors either expect domination of the CF market soon, or expansion outside this market. Vertex Pharmaceuticals is a leading play to treat cystic fibrosis .
from Biotech News
0 Comments